Recommended

Alzheimer’s IV maintenance treatment gains UK approval
Merck furthers manufacturing sustainability commitment in South Korea
FDA replaces George Tidmarsh with new CDER Director
Roche multiple sclerosis drug shows best-in-disease potential
Novartis inaugurates new US radioligand manufacturing facility
Pfizer beats Novo Nordisk in Metsera obesity biopharma offer
Stem cell research illustrates large-scale iPSC platelet manufacturing potential
CRDMO BioDuro recruits new global president, CMC
news

Moderna to obtain first acquisition for $85 million

0
SHARES

Moderna has agreed on its first acquisition for $85 million, enabling it access to cell-free DNA synthesis and amplification technologies.

Moderna to obtain first acquisition for $85 million - cell-free DNA synthesis

Moderna, Inc. is set to acquire OriCiro Genomics K.K. for $85 million, who will provide expertise on cell-free DNA synthesis and amplification technologies.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

“With this acquisition, we obtain best-in-class tools for cell-free DNA synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing,” commented Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna’s mRNA therapeutics strategy

2022 was a pivotal year for Moderna, the company‘s CEO noted in a recent statement. Moderna’s two Omicron-targeting bivalent COVID-19 vaccines have been approved in more than 70 countries. Its platform technology also delivered the world’s first-ever mRNA cancer treatment that showed efficacy in a randomised Phase II study, demonstrating the potential of personalised medicine.

At the end 2022, Moderna, Inc. finalised a strategic partnership to create a state-of-the-art mRNA vaccine research, development, and manufacturing facility in the UK. The site, called the Moderna Innovation and Technology Centre (MITC) is designed to provide access to a UK-made supply of COVID-19 vaccines. The facility also offers potential for the development of vaccines for other respiratory illnesses, such as flu and respiratory syncytial virus (RSV).

The future mRNA therapeutic market

A 2022 market report forecasted that mRNA non-vaccine therapeutics are set to generate $2 billion in sales by 2028. The research found that since the COVID-19 pandemic, there has been a spike in interest in mRNA therapeutics, due to the success of mRNA vaccines treating the virus.

mRNA therapeutics: a limitless revolution in medicine

Share via
Share via